Eli Lilly and Company Q2 2026 Earnings Recap

Lilly’s Q2 revenue growth and margin expansion outpaced expectations, driven by strong volume gains in key products like Mounjaro and Zepbound, pushing the stock up 6.8%. The market clearly rewarded the company’s robust commercial execution and positive pipeline developments.

Key Takeaways

• Revenue surged 48% year-over-year, fueled primarily by volume growth of Mounjaro, Zepbound, and contributions from Immunology, Oncology, and Neuroscience portfolios.
• Gross margin improved to 86.3%, a 1.3 percentage point increase, reflecting favorable product mix and better production costs.
• U.S. pricing declined 3% overall, or 9% excluding rebate and discount estimate adjustments, but volume growth offset price pressure.
• Non-GAAP EPS rose to $8.38, including $3.03 in acquired intangible asset charges, compared to $6.31 last year (with $0.14 in charges).
• Regulatory and commercial progress included approvals for Ebglyss maintenance dosing, Jaypirca expansions, and Foundayo launches in multiple international markets, supporting future growth prospects.